一种抗BCMA亲体亲缘性蛋白质,用于多发性骨髓瘤的治疗和诊断
Kim Anh Giang1, Johan Nilvebrant1, Hao Liu1
1Department of Protein Science, KTH-Royal Institute of Technology, SE-114 28 Stockholm, Sweden.
International journal of molecular sciences
|June 13, 2025
概括
研究人员开发了一种小小的新型蛋白质,1-E6附属体,该蛋白质针对多发性髓瘤 (MM) 的B细胞成熟抗原 (BCMA). 这种非抗体结合剂显示出新的BCMA向治疗和诊断的前景.
科学领域:
- 生物化学 生化学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 乙细胞成熟抗原 (BCMA) 是多发性骨髓瘤 (MM) 治疗的关键标.
- 目前的疗法包括双特异性T细胞参与剂和CAR T细胞,通常是基于免疫球蛋白的.
研究的目的:
- 开发针对BCMA的替代性非免疫球蛋白亲和蛋白.
- 探索面体支架在BCMA目标应用中的潜力.
主要方法:
- 使用菌体显示器开发BCMA识别的亲体库.
- 高亲缘关系结合剂的选择和表征,包括克隆1-E6.6.
- 评估结合动力学,表位图映射和基于细胞的特异性.
主要成果:
- 对BCMA具有低nM亲和力和高热稳定性的克隆1-E6的鉴定.
- 证明 1-E6 干扰 BCMA 与其连接物 APRIL 和 belantamab 的结合.
- 1-E6与BCMA阳性多发性髓瘤细胞的特定结合通过流细胞计和显微镜证实.
结论:
- 小型抗BCMA附属体1-E6代表了抗体基结合剂的有希望的替代品.
- 1-E6在开发针对多发性骨髓瘤的新型BCMA向疗法和诊断工具方面具有潜在的应用.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:31Hybridoma Technology
14.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.2K